This company has been marked as potentially delisted and may not be actively trading. NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Mallinckrodt Stock (NYSE:MNK) 30 days 90 days 365 days Advanced Chart Get Mallinckrodt alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.14▼$0.7552-Week Range N/AVolume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin. Read More Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address MNK Stock News HeadlinesMallinckrodt's $7B deal to merge with drugmaker Endo advancesJune 27, 2025 | bizjournals.comMallinckrodt and Endo Shareholders Approve MergerJune 16, 2025 | msn.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025. | Banyan Hill Publishing (Ad)Mallinckrodt and Endo Announce Leadership Plans for Transformative MergerJune 14, 2025 | msn.comMallinckrodt plc: Mallinckrodt, Endo Announce Planned Leadership Team for Merged CompanyJune 9, 2025 | finanznachrichten.deMallinckrodt and Endo Advance Key Milestones in Strategic MergerMay 19, 2025 | msn.comMalvern-Based Endo Progresses Toward Mallinckrodt Merger CompletionMay 15, 2025 | msn.comMallinckrodt and Endo Announce Significant Progress in Proposed MergerMay 14, 2025 | finance.yahoo.comSee More Headlines MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) issued its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.55. The company's quarterly revenue was down 14.9% compared to the same quarter last year. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Cos (BHC), Meta Platforms (META) and Gerdau (GGB). Company Calendar Last Earnings8/04/2020Today7/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Trailing Twelve Months)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / BookN/AMiscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NYSE:MNK) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mallinckrodt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.